icad inc. (ICAD): Price and Financial Metrics
ICAD Price/Volume Stats
Current price | $1.49 | 52-week high | $3.97 |
Prev. close | $1.59 | 52-week low | $1.05 |
Day low | $1.49 | Volume | 228,400 |
Day high | $1.65 | Avg. volume | 211,204 |
50-day MA | $1.57 | Dividend yield | N/A |
200-day MA | $1.81 | Market Cap | 39.27M |
ICAD Stock Price Chart Interactive Chart >
ICAD POWR Grades
- Sentiment is the dimension where ICAD ranks best; there it ranks ahead of 97.71% of US stocks.
- The strongest trend for ICAD is in Quality, which has been heading down over the past 26 weeks.
- ICAD ranks lowest in Momentum; there it ranks in the 4th percentile.
ICAD Stock Summary
- The ratio of debt to operating expenses for ICAD INC is higher than it is for about just 6.23% of US stocks.
- With a year-over-year growth in debt of -82.8%, ICAD INC's debt growth rate surpasses merely 1.89% of about US stocks.
- Revenue growth over the past 12 months for ICAD INC comes in at -24.11%, a number that bests merely 11.49% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ICAD, based on their financial statements, market capitalization, and price volatility, are ACRX, NURO, GNSS, APDN, and RPID.
- Visit ICAD's SEC page to see the company's official filings. To visit the company's web site, go to www.icadmed.com.
ICAD Valuation Summary
- ICAD's price/earnings ratio is -4.7; this is 116.12% lower than that of the median Healthcare stock.
- Over the past 243 months, ICAD's price/sales ratio has gone down 17.2.
Below are key valuation metrics over time for ICAD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ICAD | 2023-12-29 | 2.1 | 1.5 | -4.7 | -2.8 |
ICAD | 2023-12-28 | 2.1 | 1.5 | -4.6 | -2.7 |
ICAD | 2023-12-27 | 2.2 | 1.6 | -5.0 | -3.1 |
ICAD | 2023-12-26 | 2.2 | 1.6 | -4.9 | -3.0 |
ICAD | 2023-12-22 | 2.0 | 1.4 | -4.5 | -2.6 |
ICAD | 2023-12-21 | 2.0 | 1.4 | -4.4 | -2.5 |
ICAD Growth Metrics
- The year over year price growth rate now stands at -81.39%.
- Its 5 year net cashflow from operations growth rate is now at -29.84%.
- Its 3 year net income to common stockholders growth rate is now at -39.08%.
The table below shows ICAD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 29.262 | -11.207 | -14.707 |
2022-06-30 | 32.267 | -10.84 | -12.985 |
2022-03-31 | 32.518 | -10.294 | -13.147 |
2021-12-31 | 33.638 | -9.408 | -11.245 |
2021-09-30 | 36.282 | -8.763 | -8.702 |
2021-06-30 | 34.05 | -8.989 | -8.323 |
ICAD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ICAD has a Quality Grade of C, ranking ahead of 38.2% of graded US stocks.
- ICAD's asset turnover comes in at 0.555 -- ranking 80th of 186 Medical Equipment stocks.
- TTOO, IRMD, and DYNT are the stocks whose asset turnover ratios are most correlated with ICAD.
The table below shows ICAD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.555 | 0.714 | -0.737 |
2021-03-31 | 0.561 | 0.728 | -0.590 |
2020-12-31 | 0.628 | 0.719 | -1.587 |
2020-09-30 | 0.653 | 0.736 | -1.431 |
2020-06-30 | 0.695 | 0.752 | -1.339 |
2020-03-31 | 0.769 | 0.754 | -1.337 |
ICAD Price Target
For more insight on analysts targets of ICAD, see our ICAD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $24.00 | Average Broker Recommendation | 1.31 (Strong Buy) |
icad inc. (ICAD) Company Bio
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company was founded in 1984 and is based in Nashua, New Hampshire.
Latest ICAD News From Around the Web
Below are the latest news stories about ICAD INC that investors may wish to consider to help them evaluate ICAD as an investment opportunity.
iCAD Expands Executive Sales Leadership Team as Business GrowsBill Keyes shifts and expands his role to Senior Vice President, Global Sales Operations and Peter Graham joins iCAD as Senior Vice President, North American Sales to accelerate growth while organization adds new products and partnerships.NASHUA, N.H., Dec. 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced the expansion of its sales leadership with the addition of Peter Graham, as Senior Vice Presi |
Wealth Accumulation: 3 Stocks with Multibagger PotentialWhile it’s never easy to identify multibagger stocks, this may be one of the best times in decades to “swing for the fences” by buying undervalued growth names that are well-positioned to at least triple over the next few years. Amid excessive worries about interest rates, the Street has pushed down many unprofitable, high-potential companies’ stocks to absurdly low levels. Now that those fears are dissipating, these firms are well-positioned to make huge comebacks. Interest rates recently dropp |
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE HealthcareKey apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite*AI applications streamline workflow and support clinicians in delivering more personalized breast care, including cancer detection, density assessment, and recommendations NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence (AI) powered solutions |
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart DiseaseNew research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman’s one to two-year risk for breast canceriCAD unveils new solution that assesses calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease, the leading cause of death for women in the U.S.Dr. Emily Conant, Perelman School of Medicine, University of Pennsylvania, to present how iCAD’s 4th generation Breast AI is harnessing inn |
Discover Future Growth Stocks: 3 Penny Stocks Poised for Massive ReturnsAs the Street realizes that we're in the early stages of the business cycle, penny stocks should boom. |
ICAD Price Returns
1-mo | 2.76% |
3-mo | -3.25% |
6-mo | -22.80% |
1-year | 17.32% |
3-year | -92.04% |
5-year | -64.52% |
YTD | -15.82% |
2023 | -3.28% |
2022 | -74.58% |
2021 | -45.45% |
2020 | 69.88% |
2019 | 110.00% |
Continue Researching ICAD
Want to do more research on Icad Inc's stock and its price? Try the links below:Icad Inc (ICAD) Stock Price | Nasdaq
Icad Inc (ICAD) Stock Quote, History and News - Yahoo Finance
Icad Inc (ICAD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...